• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Substance Use & Poisoning

Pharward Biotechnology patents new E3 ubiquitin-protein ligase SIAH1 modulators to treat cocaine dependence

Feb. 1, 2024
Pharward Biotechnology Inc. Pte Ltd. has disclosed compounds acting as E3 ubiquitin-protein ligase SIAH1 modulators reported to be useful for the treatment of cocaine dependence.
Read More
Brain clay model
Neurology/Psychiatric

FDA clears IND for Jaguar’s JAG-201 for genetic form of ASD and Phelan-McDermid syndrome

Feb. 1, 2024
Jaguar Gene Therapy LLC’s IND application for JAG-201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS; 22q13.3 deletion syndrome), has been cleared by the FDA.
Read More
Immuno-oncology

Combining AMP vaccination with TCR T-cell therapies leads to improved and durable antitumor efficacy

Feb. 1, 2024
Amphiphile (AMP)-modification of peptide antigens and molecular adjuvants has been previously demonstrated to enhance lymphatic delivery and retention, resulting in potent expansion of cognate endogenous T-cell responses.
Read More
Release of malaria parasites from red blood cell
Infection

PRL-2 plays crucial role in progression to severe malaria and acute lung injury

Feb. 1, 2024
Neutrophils are the immune system’s most abundant effector cells, which play a defensive role of host cells and clear pathogens by phagocytosis, degranulation and neutrophil extracellular trap (NET) release.
Read More
Cancer

PITPNC1 induces radioresistance in rectal cancer by repressing CD8+ T-cell immunity

Feb. 1, 2024
Radiation therapy resistance (radioresistance) is a key contributor to the failure of rectal cancer treatment, with immunosuppression playing a significant role here.
Read More
Human NK cell
Immuno-oncology

23andme’s NK cell activator cleared to enter clinic for solid tumors

Feb. 1, 2024
23andme Holding Co. has received FDA clearance of its IND application for 23ME-01473 (‘1473), a dual mechanism antibody and natural killer (NK) cell activator intended to treat cancer.
Read More
Brain and DNA
Endocrine/Metabolic

Funding to advance Vivet’s gene therapy for cerebrotendinous xanthomatosis

Feb. 1, 2024
Vivet Therapeutics SAS has been awarded financing of €4.9 million (US$5.3 million) from the French government to advance the development of a gene therapy for the treatment of the neurodegenerative disease cerebrotendinous xanthomatosis (CTX).
Read More
Doctor with illustration of kidneys
Nephrology

Guard Therapeutics outlines progress within preclinical peptide platform targeting chronic diseases

Feb. 1, 2024
Guard Therapeutics AB has presented progress within the company’s preclinical development platform, the GTX platform, aimed at developing new peptides based on the endogenous protein α-1-microglobulin.
Read More
Neurology/Psychiatric

Natural product counteracts perioperative neurocognitive disorder

Feb. 1, 2024
Perioperative neurocognitive disorders (PNDs) refer to a variety of cognitive abnormalities mainly experienced by elderly patients after anesthesia procedures and include cognitive impairment and disorientation linked to oxidative stress and neuroinflammation. Insulin-like growth factor-1 (IGF-1), a neurotrophic hormone that regulates microglia-mediated neuroinflammation, may represent a therapeutic target in this context.
Read More
3D illustration of tumor
Cancer

CD276 identified as new therapeutic target in brain malignancies

Jan. 31, 2024
Researchers from University of Lausanne have published data from a study that aimed to analyze the key components of the brain tumor vasculature in order to better understand the mechanisms of brain metastasis (BrM).
Read More
Previous 1 2 … 546 547 548 549 550 551 552 553 554 … 17794 17795 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 24, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe